Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 5:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,730 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tumor, Neuroendocrine Clear all
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00085488
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
autologous tumor cell vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Sep 22, 2026, 5:50 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

NCT04792073
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
Avelumab, Comprehensive Ablative Radiation Therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 22, 2026, 5:50 PM EDT
Terminated Phase 2 Interventional

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

NCT04375527
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8, Locally Advanced Cutaneous Melanoma, Metastatic Cutaneous Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC V8, Pathologic Stage IIIA Cutaneous Melanoma AJCC V8, Pathologic Stage IIIB Cutaneous Melanoma AJCC V8, Pathologic Stage IIIC Cutaneous Melanoma AJCC V8, Pathologic Stage IIID Cutaneous Melanoma AJCC V8, Pathologic Stage IV Cutaneous Melanoma AJCC V8, Unresectable Cutaneous Melanoma
Interventions
Binimetinib, Nivolumab, Questionnaire Administration
Drug · Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 2 Interventional

Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma

NCT00027742
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
pegylated interferon alfa, temozolomide
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 22, 2026, 5:50 PM EDT
Recruiting Phase 1 Interventional

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

NCT06529822
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer
Interventions
Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera or Altera testing
Biological · Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
3
States / cities
Orlando, Florida • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 2 Interventional

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

NCT00005961
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
13
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 22, 2026, 5:50 PM EDT
Active, not recruiting Phase 1 Interventional

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

NCT03025256
View directory record Official record
Conditions
Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm, Melanocytoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

NCT03629756
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer
Interventions
Etrumadenant, Zimberelimab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Risk Information and Skin-cancer Education for Undergraduate Prevention

NCT03979872
View directory record Official record
Conditions
Melanoma, Young Adult
Interventions
MC1R Genetic Testing, Skin Cancer Education, UV Photo
Diagnostic Test · Other · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 22, 2026, 5:50 PM EDT
Not listed Phase 2 Interventional

Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma

NCT01565837
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Stereotactic Ablative Radiosurgery (SART)
Drug · Radiation
Lead sponsor
Wolfram Samlowski
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 22, 2026, 5:50 PM EDT
Recruiting Phase 1 Interventional

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

NCT06062745
View directory record Official record
Conditions
Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
Interventions
18F-fluciclovine, PET/CT
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Early Phase 1 Interventional

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

NCT05704933
View directory record Official record
Conditions
Metastatic Melanoma, Metastasis to Brain
Interventions
Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Standard of Care Craniotomy
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

NCT04670445
View directory record Official record
Conditions
Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma, Unresectable Stage III Non-Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Stage IV Merkel Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma, Stage IV Basal Cell Carcinoma, Stage IV Breast Cancer, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Hepatocellular Cancer, Stage IV Renal Cell Carcinoma, Stage IV Bladder Cancer, Stage IV Head and Neck Squamous Cell Carcinoma, Stage IV Cervical Cancer, Stage IV Endometrial Cancer, Stage IV Mesothelioma, Immunotherapy, Immune Checkpoint Inhibitors
Interventions
Educational Video and QPL List, Usual Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00004604
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
CEA RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 2 Interventional

Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors

NCT00004922
View directory record Official record
Conditions
Carcinoma of Unknown Primary, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma of the Skin
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 1 Interventional

Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

NCT01665183
View directory record Official record
Conditions
Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Not applicable Interventional

Eversion in Dermatologic Surgery: Is Cosmetic Appearance Improved?

NCT01770002
View directory record Official record
Conditions
Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
Interventions
Everted suture technique, Non-everted suture technique
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 3 Interventional

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

NCT00257205
View directory record Official record
Conditions
Melanoma
Interventions
dacarbazine, CP-675,206, temozolomide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
55
States / cities
Huntsville, Alabama • Mobile, Alabama • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2012 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 1 Interventional

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

NCT01469572
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Pasireotide, Sir-sphere Radioembolization, Everolimus
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 22, 2026, 5:50 PM EDT
Completed Phase 1 Interventional

In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer

NCT00631072
View directory record Official record
Conditions
Malignant Melanoma
Interventions
INKT, GM-CSF
Biological · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 22, 2026, 5:50 PM EDT
Terminated Phase 2 Interventional

CP-461 in the Treatment of Patients With Advanced Melanoma

NCT00060710
View directory record Official record
Conditions
Malignant Melanoma
Interventions
CP-461
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2011 · Synced Sep 22, 2026, 5:50 PM EDT
Terminated No phase listed Observational

Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

NCT00991991
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
gene expression analysis, polymerase chain reaction, polymorphism analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, medical chart review
Genetic · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 22, 2026, 5:50 PM EDT
Terminated Not applicable Interventional

3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed With Melanoma

NCT03825913
View directory record Official record
Conditions
Melanoma
Interventions
Exercise Intervention, Wellness Intervention
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 22, 2026, 5:50 PM EDT
Active, not recruiting Phase 1 Interventional

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

NCT05075993
View directory record Official record
Conditions
Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic HPV Related Solid Tumors, Metastatic Ovarian Carcinoma, Metastatic Soft Tissue Sarcoma, Metastatic Uveal Melanoma
Interventions
LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 22, 2026, 5:50 PM EDT